期刊文献+

肿瘤坏死因子抑制剂治疗银屑病关节炎2例 被引量:3

肿瘤坏死因子抑制剂治疗银屑病关节炎2例
原文传递
导出
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第15期1213-1214,共2页 Chinese Journal of Practical Internal Medicine
关键词 肿瘤坏死因子抑制剂 银屑病关节炎 Tumor necrosis factor inhibitor Psoriatic arthritis
  • 相关文献

参考文献6

  • 1Nash PT,Florin TH.Tumour necrosis factor inhibitors[J].Med J Aust,2005,183(4):205-208. 被引量:1
  • 2Moreland LW,Weinblatt ME,Keystone EC,et al.Etanercept treatment in adults with established rheumatoid arthritis:7 years of clinical experience[J].J Rheum,2006,33(5):854-861. 被引量:1
  • 3Mease PJ.Etanercept:a new era in the treatment of psoriatic arthritis[J].Am J Manag Care,2002,46(5):1171-1176. 被引量:1
  • 4Papp KA,Tyring S,Lahfa M,et al.A global phase Ⅲ randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction[J].Br J Dermat,2005,152:1304-1312. 被引量:1
  • 5Mease PJ,Goffe BS,Metz J,et al.Etanercept in the treatment of psoriatic arthritis and psoriasis:a randomized trial[J].Lancet,2000,356:385-390. 被引量:1
  • 6Shin IS,Baer AN,Kwon HJ,et al.Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy[J].Arth Rheum,2006,54(5):1429-1434. 被引量:1

同被引文献65

  • 1李先平,李晶,王皓,郭亚军.银屑病生物治疗研究进展[J].中国医药生物技术,2007,2(3):207-211. 被引量:8
  • 2何坚,唐福林.银屑病关节炎的药物治疗[J].中华风湿病学杂志,2004,8(11):690-692. 被引量:6
  • 3陆威,劳力民.关节病性银屑病发病机制及生物制剂治疗的进展[J].国外医学(皮肤性病学分册),2005,31(6):348-351. 被引量:2
  • 4张小娟,纪维,党文义,金汤.生物制剂治疗银屑病的进展[J].西北药学杂志,2007,22(3). 被引量:3
  • 5Mease PJ, Kivitz A J, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumato1,2006 ,33 :712-721. 被引量:1
  • 6de Vlam K,Lories RJ. Efficacy,effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) ,2006,45 : 321-324. 被引量:1
  • 7Gottlieb AB,Kircik L,Eisen D,et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care and Treatment with Etanercept(EDUCATE) study. J Dermatolog Treat,2006,17:343-352. 被引量:1
  • 8Haake H, Koneke J ,Amann K ,et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin ( Munich ), 2007, 102 : 852-857. 被引量:1
  • 9Kaey S,Worm M,Audring H,et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis, 2006,65: 405 -407. 被引量:1
  • 10Antoni CE, Kavanaugh A, vander Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial(IMPACT). J Rheumatol,2008 ,35:869-876. 被引量:1

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部